Dr. Izzy’s FDA Radar

Catalyst Calendar

35 verified events
More filters

Exact dates (6)

povetacicept

November 30, 2026

Target timing

View details

VERTEX PHARMACEUTICALS INC / MA

FDA target date

IgAN

Phase 3

NCT06564142

Announced Nov 2, 2026

Announced timing: November 30, 2026

Original source

Want a quick AI summary?

ARIKAYCE · Mycobacterium avium complex

January 28, 2027

Target timing

View details

INSMED Inc

FDA target date

Mycobacterium avium complex (MAC) lung disease

Announced Oct 29, 2026

Announced timing: January 28, 2027

Original source

Want a quick AI summary?

VOXZOGO · achondroplasia

February 28, 2027

Target timing

View details

BIOMARIN PHARMACEUTICAL INC

FDA target date

achondroplasia

Announced Nov 2, 2026

Announced timing: February 28, 2027

Original source

Want a quick AI summary?

lonvo-z

March 10, 2027

Target timing

View details

Intellia Therapeutics, Inc.

FDA target date

Announced Nov 5, 2026

Announced timing: March 10, 2027

Original source

Want a quick AI summary?

AXS-12 · cataplexy in narcolepsy

May 1, 2027

Target timing

View details

Axsome Therapeutics, Inc.

FDA target date

cataplexy in narcolepsy

Announced Nov 2, 2026

Announced timing: May 1, 2027

Original source

Want a quick AI summary?

VOXZOGO · HCH

May 30, 2027

Target timing

View details

BIOMARIN PHARMACEUTICAL INC

FDA target date

HCH

Announced Nov 2, 2026

Announced timing: May 30, 2027

Original source

Want a quick AI summary?

Announced months (4)

Ordspono

February 2027

Target timing

View details

REGENERON PHARMACEUTICALS, INC.

FDA target date

relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Announced Oct 30, 2026

Announced timing: February 2027

Original source

Want a quick AI summary?

ALN-2232 · clinical data

February 2027

Expected window

View details

ALNYLAM PHARMACEUTICALS, INC.

Clinical readout

obesity and weight management

Phase 1

Announced Oct 29, 2026

Announced timing: February 2027

Original source

Want a quick AI summary?

ALN-6400 · clinical data

February 2027

Expected window

View details

ALNYLAM PHARMACEUTICALS, INC.

Clinical readout

hereditary hemorrhagic telangiectasia (HHT)

Phase 2

NCT06659640

Announced Oct 29, 2026

Announced timing: February 2027

Original source

Want a quick AI summary?

Libtayo

March 2027

Target timing

View details

REGENERON PHARMACEUTICALS, INC.

FDA target date

Announced Oct 30, 2026

Announced timing: March 2027

Original source

Want a quick AI summary?

Broad windows (25)

ABP 206

By year-end 2026

Company expectation · not a PDUFA date

View details

AMGEN INC

Expected FDA action

treatment-naïve unresectable or metastatic melanoma

Announced Nov 3, 2026

Announced timing: By year-end 2026

Original source

Want a quick AI summary?

BROADEN2

By year-end 2026

Expected window

View details

Kymera Therapeutics, Inc.

Clinical readout

moderate to severe AD

Phase 2b

NCT07217015

Announced Oct 29, 2026

Announced timing: By year-end 2026

Original source

Want a quick AI summary?

Sefaxersen IMAgINATION data

2027

Expected window

View details

IONIS PHARMACEUTICALS INC

Clinical readout

IgAN

Phase 3

Announced Nov 9, 2026

Announced timing: 2027

Original source

Want a quick AI summary?

inaxaplin · interim analysis data

early 2027

Expected window

View details

VERTEX PHARMACEUTICALS INC / MA

Clinical readout

Announced Nov 2, 2026

Announced timing: early 2027

Original source

Want a quick AI summary?

povetacicept · gMG data

H1 2027

Expected window

View details

VERTEX PHARMACEUTICALS INC / MA

Clinical readout

gMG

Phase 2

Announced Nov 2, 2026

Announced timing: H1 2027

Original source

Want a quick AI summary?

suzetrigine · clinical data

mid 2027

Expected window

View details

VERTEX PHARMACEUTICALS INC / MA

Clinical readout

diabetic peripheral neuropathy (DPN)

Phase 3

Announced Nov 2, 2026

Announced timing: mid 2027

Original source

Want a quick AI summary?

VX-993 · clinical data

mid 2027

Expected window

View details

VERTEX PHARMACEUTICALS INC / MA

Clinical readout

DPN

Phase 2

Announced Nov 2, 2026

Announced timing: mid 2027

Original source

Want a quick AI summary?

BMN 333 · clinical data

2027

Expected window

View details

BIOMARIN PHARMACEUTICAL INC

Clinical readout

achondroplasia

Phase 2/3

NCT07441876

Announced Nov 2, 2026

Announced timing: 2027

Original source

Want a quick AI summary?

BMN 440

2027

Expected window

View details

BIOMARIN PHARMACEUTICAL INC

Clinical readout

hypophosphatasia (HPP)

Phase 1/2a

Announced Nov 2, 2026

Announced timing: 2027

Original source

Want a quick AI summary?

ENGAGE

Q1 2027

Timing updated

Expected window

View details

Axsome Therapeutics, Inc.

Clinical readout

Binge Eating Disorder

Phase 3

Announced Nov 2, 2026

Announced timing: Q1 2027

Original source

Want a quick AI summary?

VK2735 · maintenance Part 2 results

2027

Expected window

View details

Viking Therapeutics, Inc.

Clinical readout

Announced Oct 28, 2026

Announced timing: 2027

Original source

Want a quick AI summary?

Colorectal cancer clinical data update

H1 2027

Timing updated

Expected window

View details

Revolution Medicines, Inc.

Clinical readout

Announced Nov 4, 2026

Announced timing: H1 2027

Original source

Want a quick AI summary?

RASolve 301

2027

Expected window

View details

Revolution Medicines, Inc.

Clinical readout

previously treated RAS mutant NSCLC

Phase 3

NCT06881784

Announced Nov 4, 2026

Announced timing: 2027

Original source

Want a quick AI summary?

RMC-5127

2027

Expected window

View details

Revolution Medicines, Inc.

Clinical readout

Announced Nov 4, 2026

Announced timing: 2027

Original source

Want a quick AI summary?

ARV-393 · additional monotherapy data

mid 2027

Expected window

View details

ARVINAS, INC.

Clinical readout

B- and T-cell lymphomas

Phase 1

NCT06393738

Announced Nov 3, 2026

Announced timing: mid 2027

Original source

Want a quick AI summary?

ARV-393 · combination data

mid 2027

Expected window

View details

ARVINAS, INC.

Clinical readout

DLBCL

Phase 1

NCT06393738

Announced Nov 3, 2026

Announced timing: mid 2027

Original source

Want a quick AI summary?

BREADTH

late 2027

Expected window

View details

Kymera Therapeutics, Inc.

Clinical readout

moderate to severe eosinophilic asthma

Phase 2b

Announced Oct 29, 2026

Announced timing: late 2027

Original source

Want a quick AI summary?

REVEAL

H2 2027

Expected window

View details

IONIS PHARMACEUTICALS INC

Clinical readout

Angelman syndrome

Phase 3

Announced Nov 9, 2026

Announced timing: H2 2027

Original source

Want a quick AI summary?

FOCUS-2

H2 2027

Expected window

View details

Axsome Therapeutics, Inc.

Clinical readout

children with ADHD

Phase 3

Announced Nov 2, 2026

Announced timing: H2 2027

Original source

Want a quick AI summary?

FOCUS-3

H2 2027

Expected window

View details

Axsome Therapeutics, Inc.

Clinical readout

adolescents with ADHD

Phase 3

Announced Nov 2, 2026

Announced timing: H2 2027

Original source

Want a quick AI summary?

SUMMIT

H2 2027

Expected window

View details

Axsome Therapeutics, Inc.

Clinical readout

smoking cessation

Phase 3

Announced Nov 2, 2026

Announced timing: H2 2027

Original source

Want a quick AI summary?

SUSTAIN

H2 2027

Timing updated

Expected window

View details

Axsome Therapeutics, Inc.

Clinical readout

Shift Work Disorder

Phase 3

Announced Nov 2, 2026

Announced timing: H2 2027

Original source

Want a quick AI summary?

ARV-6723 · clinical data

H2 2027

Expected window

View details

ARVINAS, INC.

Clinical readout

Announced Nov 3, 2026

Announced timing: H2 2027

Original source

Want a quick AI summary?

BMN 820 · clinical data

2028

Expected window

View details

BIOMARIN PHARMACEUTICAL INC

Clinical readout

focal segmental glomerulosclerosis (FSGS)

Phase 3

Announced Nov 2, 2026

Announced timing: 2028

Original source

Want a quick AI summary?

VANQUISH · extension study results

2028

Expected window

View details

Viking Therapeutics, Inc.

Clinical readout

Announced Oct 28, 2026

Announced timing: 2028

Original source

Want a quick AI summary?

Source coverage

SEC 8-K filings and their exhibits from the last 90 days are scanned daily for 20 tracked companies: REGN, RVMD, IONS, AMGN, ISRG, TEM, BBNX, GH, VRTX, ALNY, INSM, SRPT, BMRN, NTLA, BEAM, KYMR, ARVN, PTCT, AXSM, VKTX. A successful scan with no qualifying events means none were verified in those sources; a failed scan retains previously verified data and is recorded separately as a source error. Later filings are checked for revisions, cancellations and announced results; unresolved timing conflicts are withheld. Blocked IR feeds and unverified company links are excluded. Not a complete catalyst inventory.